US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 21:54:43 Source:businessViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:JoJo Siwa goes wild: Karma singer accused of getting drunk at Disney World after turning 21
Next:Pope trip to Luxembourg, Belgium confirmed for September, 2 weeks after challenging Asia visit
You may also like
- Jessica Biel CHOPS her long locks into a bob after book signing in Studio City
- Louisiana lawmakers reject adding exceptions of rape and incest to abortion ban
- More GOP states challenge federal rules protecting transgender students
- Closing prices for crude oil, gold and other commodities
- Verona confirms Serie A status for another year after beating Salernitana
- REVEALED: New PROOF the anti
- 3 arrested in NYC after driver strikes pro
- New Mexico high court upholds man's 3 murder convictions in 2018 shooting deaths near Dixon
- Storms damage homes in Oklahoma and Kansas. But in Houston, most power is restored